The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1477633
Current research status and trends of potassium-competitive acid blockers in the treatment of acid-related diseases: a bibliometric analysis
Provisionally accepted
Baoqiang Zhu
1
Long Chen
1*
Xue Tao
2
Hong Zheng
1*
Xia Li
1*
Qingfang Wu
1
Enwu Long
2
Haixia Lin
1*- 1 The First People’s Hospital of Shuangliu District, Chengdu, Chengdu, China
- 2 Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, China
To explore the current research status and trends of potassium-competitive acid blockers (P-CABs) in the treatment of acid related diseases (ARDs) using bibliometric analysis.We collected publications related to P-CAB in the treatment of acid-related diseases in the Web of Science (WOS) Core Collection from the establishment of the database to June 30, 2024. We evaluated the publication volume and citation status over the years using the WOS platform, and visualized the authors, countries, institutions, keywords, and citations of the publications using CiteSpace and VOSviewer.Results: This study included a total of 455 articles. The number of publications and citations related to research has been increasing year by year. The results show that the scholars with the highest number of publications mainly come from South Korea and Japan. Scholars such as Geun Seog Song, Bongtae Kim, and Nobuhiro Inatomi produced many works in related fields. The most popular drug in this field was vonoprazan, and research on this drug mainly focused on the effectiveness and safety evaluation of ARDs such as Helicobacter pylori infection, gastroesophageal reflux disease, peptic ulcers, etc. Researchers were concerned about the evaluation of treatment regimens and efficacy comparison between P-CABs and traditional proton pump inhibitors (PPIs) in the treatment of ARDs. At the same time, researchers are also closely monitoring the potential adverse reactions and long-term adverse outcomes of clinical application of P-CABs for ARDs.The clinical application of P-CABs, represented by vonoprazan, in ARDs is receiving widespread attention from researchers. The exploration of the application of this type of drug in ARDs is constantly expanding, and it is a research field with great clinical value and research potential.
Keywords: Potassium-competitive acid blocker, Acid-related diseases, Bibliometric, Citespace, VOSviewer
Received: 08 Aug 2024; Accepted: 16 Dec 2024.
Copyright: © 2024 Zhu, Chen, Tao, Zheng, Li, Wu, Long and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Long Chen, The First People’s Hospital of Shuangliu District, Chengdu, Chengdu, China
Hong Zheng, The First People’s Hospital of Shuangliu District, Chengdu, Chengdu, China
Xia Li, The First People’s Hospital of Shuangliu District, Chengdu, Chengdu, China
Haixia Lin, The First People’s Hospital of Shuangliu District, Chengdu, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.